The Burden of Lyme Disease (BOLD) in a Pandemic - Insights From an Online Cross-sectional and Prospective Cohort Survey

Overview

A cross-sectional descriptive survey of the BOLD for individuals after having been ill with COVID-19 or have taken the COVID-19 vaccine will be compared with that of individuals who have neither been ill with COVID-19 nor taken the COVID-19 vaccine. Individuals who have both been ill and taken the COVID-19 vaccine will be compared to identify any additive risk factors.

Primary research question: 1\. Will the BOLD be worse for individuals who have taken the COVID-19 vaccine? Secondary research questions: 1. Will the BOLD be worse for individuals who have been ill with COVID-19? 2. What factors affect the BOLD in individuals a) after having been ill with COVID-19, and b) in those who have taken the COVID-19 vaccine? Do they differ? 3. If BOLD risk factors specific to either the COVID-19 vaccine or having been ill with COVID-19 are found, are they additive in people who have experienced both? 4. What is the prevalence of hesitancy in the Lyme disease community to the COVID-19 vaccine? 5. What is the severity of symptoms most likely to predict functional problems in individuals with Lyme disease who have been ill with COVID-19 or taken the COVID-19 vaccine?

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Central Contacts